| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442519 | European Journal of Cancer | 2015 | 11 Pages |
Abstract
Our results suggest that continuing vemurafenib treatment beyond progression may be beneficial in advanced melanoma patients, who prior to progression responded to vemurafenib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A. Scholtens, M.H. Geukes Foppen, C.U. Blank, J.V. van Thienen, H. van Tinteren, J.B. Haanen,